Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

289 - Local disease control of nasal malignant melanoma achieved by administration of nivolumab followed by palliative radiation: a case report


24 Nov 2018


Poster display - Cocktail


End-of-Life Care;  Immunotherapy;  Radiation Oncology

Tumour Site



TOMOKO Yamazaki


T. Yamazaki

Author affiliations

  • Head And Neck Cancer Oncology, Miyagi Cancer Center, 981-1293 - Natori/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 289

Case Summary

A 57-year-old man was diagnosed with locally advanced left nasal malignant melanoma three years ago at another hospital. He had achieved a complete response after receiving heavy particle treatment (57.6 Gy/16 fr) followed by chemotherapy (DAV: dacarbazine, nimustine, vincristine). However, multiple lung metastases were detected by computed tomography (CT) one year ago and he was referred to our hospital. He was treated with four doses of ipilimumab. There was no change in tumor size and he underwent follow-up. He subsequently noticed a swelling of the upper left gingiva at 56 years old. CT revealed multiple metastases in the nasal cavity, maxillary sinus and gingiva, as well as mediastinal lymph node metastasis and progression of the multiple lung metastases. Biopsy of the maxillary sinus showed malignant melanoma. He received seven doses of nivolumab. However, there was local tumor progression and he became anemic due to persistent nasal bleeding. He received palliative radiation (30 Gy/10 fr) for the locally recurrent tumor. Nasal bleeding stopped after radiation and his anemia improved, although there was a mild increase in the size of the lung metastasis. Nivolumab was restarted. Our findings demonstrate that radiation after immunotherapy was effective for controlling nasal malignant melanoma in this patient.

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.